IL-12, IL-23 and IL-17 in IBD: Therapeutic and immunobiology targeting

The occurrence of multiple infections within the human body, such as gastroenteritis, is observed in a subset patients who also experience inflammation-related conditions like ulcerative colitis. Traditionally, these have been associated with an excessive response from Th2 or Th1 cells, respectively. However, recent studies unveiled noteworthy revelation in. context Inflammatory Bowel Disease (IBD). It has demonstrated that enhancement cytokine synthesis facilitated by distinctive T specifically Th17 known helper cells. This discovery marks pivotal development field immunopathology. Furthermore, role interleukin (IL)-23 amplifying cell responses, including those inflammatory bowel disease, yielded valuable insights into tissue damage pathways and opened up new avenues for therapeutic strategies various diseases, notably disease. Recent research shed light on potential dual nature Th17- cytokines, IL-22 IL-17A, which may exert protective effects without causing harm. comprehensive review underscores played cells IL-23 processes occurring tissues, affected intestinal other related conditions.